ARMO BioSciences (NASDAQ:ARMO) Receiving Somewhat Favorable News Coverage, Study Shows

Headlines about ARMO BioSciences (NASDAQ:ARMO) have trended somewhat positive recently, Accern reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. ARMO BioSciences earned a coverage optimism score of 0.20 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.3453943000633 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:

• BRIEF-Armo Biosciences Enrolls Patient In The Cypress 2 Trial Evaluating AM0010 (reuters.com)
• ARMO BioSciences Enrolls First Patient in the CYPRESS 2 Trial Evaluating AM0010 in Non-Small Cell Lung Cancer (finance.yahoo.com)
• ARMO BioSciences Expected to Post FY2017 Earnings of ($2.40) Per Share (ARMO) (americanbankingnews.com)
• ARMO BioSciences (ARMO) Expected to Post Earnings of -$0.12 Per Share (americanbankingnews.com)
• Leerink: Armo Biosciences’ ‘Promising’ Data Justifies A Bullish Stance (msn.com)

Shares of NASDAQ:ARMO traded up $0.25 during mid-day trading on Thursday, reaching $37.41. 224,044 shares of the company’s stock were exchanged, compared to its average volume of 245,630. ARMO BioSciences has a twelve month low of $27.00 and a twelve month high of $57.19.

ARMO has been the topic of a number of research analyst reports. Jefferies Group initiated coverage on shares of ARMO BioSciences in a research report on Tuesday, February 20th. They issued a “buy” rating and a $61.00 target price on the stock. Leerink Swann restated a “market perform” rating on shares of ARMO BioSciences in a research report on Tuesday, February 20th. Robert W. Baird began coverage on shares of ARMO BioSciences in a research report on Tuesday, February 20th. They issued an “outperform” rating and a $67.00 target price on the stock. Finally, BMO Capital Markets began coverage on shares of ARMO BioSciences in a report on Tuesday, February 20th. They set an “outperform” rating and a $75.00 price target on the stock.

ILLEGAL ACTIVITY NOTICE: This story was first posted by BBNS and is owned by of BBNS. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://baseballnewssource.com/2018/03/29/armo-biosciences-armo-earns-news-sentiment-score-of-0-20/1971628.html.

ARMO BioSciences Company Profile

ARMO Biosciences, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on developing immunotherapies for the treatment of cancer, cardiovascular disease, fibrosis and inflammation. The Company’s platform molecule AM0010 is a pegylated form of recombinant human IL-10, which has immune stimulating effects that induce the activation, proliferation and survival of intratumoral, tumor-reactive, cytotoxic CD8+ T cells in cancer patients.

Receive News & Ratings for ARMO BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARMO BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.